Brief: Precigen Receives Breakthrough Therapy Designation For PRGN-2012 Adenoverse Immunotherapy For The Treatment Of Recurrent Respiratory Papillomatosis

Precigen

20/06/2023 12:36

June 20 (Reuters) - Precigen Inc  PGEN.O :
    * PRECIGEN RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR
PRGN-2012
ADENOVERSE™ IMMUNOTHERAPY FOR THE TREATMENT OF RECURRENT
RESPIRATORY PAPILLOMATOSIS
    * PRECIGEN- POSITIVE PHASE1 CLINICAL DATA SHOWED 50%
PATIENTS
"SURGERY-FREE" AFTER PRGN-2012 TREATMENT WITH MINIMUM FOLLOW UP
OF 12 MONTHS POST-TREATMENT
    * PRECIGEN INC-PRGN-2012 WAS WELL-TOLERATED WITH NO
DOSE-LIMITING
TOXICITIES AND NO TREATMENT-RELATED ADVERSE EVENTS GREATER THAN
GRADE 2
    * PRECIGEN INC-PHASE 1 CLINICAL EVIDENCE DEMONSTRATING
SAFETY AND
EFFICACY OF PRGN-2012 FOR TREATMENT OF RRP PATIENTS

Source text for Eikon:  ID:nPnv954za 
Further company coverage:  PGEN.O 

 ((reuters.briefs@thomsonreuters.com;))